Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

• Status: Unknown status
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Coronary heart disease has a high incidence and high death rate. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD). However, PCI may cause myocardial cell injury and myocardial infarction 4 Type(MI4a, Type 4 a myocardial infarction related to PCI). Dexmedetomidine(Dex) is the only anesthetic which has sedative and analgesic effects. Dex currently has been widely used in perioperative management of various surgical.This study intends to verify the effect of heart protection of Dex in perioperative.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Dexmedetomidine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• the patients were coincided to CHD combined with depression and anxiety according to diagnostic standard of World Health Organization(WHO)who need receive selective PCI in the First Affiliated Hospital of Xi'an Jiaotong University;

• people aged over 18;

• patients who will undergo PCI with Hamilton Anxiety scale of 14 points or more.

Exclusion Criteria:

• severe comorbidity history;

• coronary stenosis less than 70%;

• severe cardiac dysfunction;

• central nervous system disease;

• troponin I levels have rised before entering the hospital;

• pregnant woman；

• history of mental disorders;

• alcoholic and long-term use of sedatives and opioids history;

• drug allergy history.